---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-062935"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2026-05-29T21:10:41+00:00"
generated_at: "2026-05-29T21:12:37.803596+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

## Summary
- Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
- Must submit compliance plan by June 26, 2026; deadline to regain compliance by November 27, 2027.
- Company announced three ATNM-400 presentations at SNMMI 2026 (May 31-June 2) showing preclinical data in prostate cancer and NSCLC.
- If plan not accepted or compliance not regained, delisting proceedings will commence; no immediate effect on trading.

## SEC filing metadata
- accession: 0001213900-26-062935
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2026-05-29T21:10:41+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-062935
- JSON: https://secwatch.observer/filing/0001213900-26-062935.json
- Plain text: https://secwatch.observer/filing/0001213900-26-062935.txt

## Source-grounded claims
- claim_id: 8025b29d0e73741c3ec7d9898fa2e5256dcf5dcc
  claim: Actinium Pharmaceuticals, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).
  evidence_excerpt: May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.